Chemotherapy, immunotherapy, or combination first-line treatment for metastatic urothelial carcinoma of the bladder: a large real-world experience
S Ranganathan, C Riveros, J Xu, S Hu, M Geng… - … Oncology: Seminars and …, 2024 - Elsevier
Introduction First-line systemic therapy for metastatic urothelial carcinoma of the bladder
(mUC) consists of platinum-based chemotherapy in most patients and PD1/L1 inhibitors in …
(mUC) consists of platinum-based chemotherapy in most patients and PD1/L1 inhibitors in …
[HTML][HTML] Pharmaceutical policy, impact and health outcomes
HY Kwon, B Godman - Frontiers in Pharmacology, 2023 - frontiersin.org
Pharmaceutical policy is essential given increasing expenditure on medicines and only finite
resources, with global expenditure on medicines estimated to reach US $1.5 trillion by the …
resources, with global expenditure on medicines estimated to reach US $1.5 trillion by the …